Assignee
DA VOLTERRA
FR·7 granted patents·6 pending applications·26 citations·filing 2003–2022
Top patents by PatentIndex Score
13 records- 0190US10052288B2Formulations for oral delivery of adsorbents in the gutDA VOLTERRA·Filed 2017·Granted Aug 21, 2018·11 cites·21 claims
- 0277US11365403B2Beta-lactamase variantsDA VOLTERRA·Filed 2018·Granted Jun 21, 2022·1 cites·16 claims
- 0376US7485294B2Galenic pectinate formulation for colon-targeted delivery of antibiotic-inactivating enzymes and method of use thereofDA VOLTERRA·Filed 2003·Granted Feb 3, 2009·11 cites·14 claims
- 0474US10982205B2Beta-lactamase variantsDA VOLTERRA·Filed 2017·Granted Apr 20, 2021·1 cites·20 claims
- 0572US10988749B2Beta-lactamase variantsDA VOLTERRA·Filed 2017·Granted Apr 27, 2021·1 cites·16 claims
- 0671US2022087945A1Formulations for oral delivery of adsorbents in the gutDA VOLTERRA·Filed 2021·Application pending·0 cites
- 0770US7833765B2Galenic formulation for colon-targeted delivery of active ingredientsDA VOLTERRA·Filed 2008·Granted Nov 16, 2010·1 cites·31 claims
- 0869US11202761B2Formulations for oral delivery of adsorbents in the gutDA VOLTERRA·Filed 2018·Granted Dec 21, 2021·0 cites·29 claims
- 0965US2022356459A1Beta-lactamase variantsDA VOLTERRA·Filed 2022·Application pending·0 cites
- 1057US2021008096A1Suppression or reduction of the pathogenicity or virulence of a clostridium bacteriaDA VOLTERRA·Filed 2020·Application pending·0 cites
- 1149US2021299170A1Method for improving anticancer agent efficacyDA VOLTERRA·Filed 2019·Application pending·0 cites
- 1249US2021290741A1Compositions for the treatment of graft versus host diseaseDA VOLTERRA·Filed 2019·Application pending·0 cites
- 1341US2018303867A1Suppression or reduction of the pathogenicity or virulence of a clostridium bacteriaDA VOLTERRA·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →